Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Replimune Group stock
Learn how to easily invest in Replimune Group stock.
Replimune Group Inc is a biotechnology business based in the US. Replimune Group shares (REPL) are listed on the NASDAQ and all prices are listed in US Dollars. Replimune Group employs 206 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Replimune Group
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – REPL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Replimune Group stock price (NASDAQ: REPL)Use our graph to track the performance of REPL stocks over time.
Replimune Group shares at a glance
|Latest market close||$15.88|
|52-week range||$13.05 - $35.93|
|50-day moving average||$19.11|
|200-day moving average||$18.96|
|Wall St. target price||$45.60|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.26|
Buy Replimune Group shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Replimune Group stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Replimune Group price performance over time
|1 week (2022-09-20)||-1.55%|
|1 month (2022-08-26)||-17.16%|
|3 months (2022-06-27)||-11.38%|
|6 months (2022-03-25)||-0.69%|
|1 year (2021-09-27)||-50.84%|
|2 years (2020-09-25)||-25.66%|
|3 years (2019-09-27)||18.51%|
|5 years (2017-09-23)||N/A|
Replimune Group financials
|Gross profit TTM||$0|
|Return on assets TTM||-16.35%|
|Return on equity TTM||-29.91%|
|Market capitalisation||$783 million|
TTM: trailing 12 months
Replimune Group share dividends
We're not expecting Replimune Group to pay a dividend over the next 12 months.
Replimune Group share price volatility
Over the last 12 months, Replimune Group's shares have ranged in value from as little as $13.05 up to $35.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Replimune Group's is 1.9564. This would suggest that Replimune Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Replimune Group overview
Replimune Group, Inc. , a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Frequently asked questionsWhat percentage of Replimune Group is owned by insiders or institutions?
Currently 8.966% of Replimune Group shares are held by insiders and 94.877% by institutions. How many people work for Replimune Group?
Latest data suggests 206 work at Replimune Group. When does the fiscal year end for Replimune Group?
Replimune Group's fiscal year ends in March. Where is Replimune Group based?
Replimune Group's address is: 500 Unicorn Park Drive, Woburn, MA, United States, 01801 What is Replimune Group's ISIN number?
Replimune Group's international securities identification number is: US76029N1063 What is Replimune Group's CUSIP number?
Replimune Group's Committee on Uniform Securities Identification Procedures number is: 76029N106
More guides on Finder
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
Ask an Expert